Bupivacaine HCl 0.375% w/v and Lidocaine HCl 2% w/v Solution for Retrobulbar or Peribulbar Inject...

FDA Recall #D-1514-2022 — Class II — July 27, 2022

Recall #D-1514-2022 Date: July 27, 2022 Classification: Class II Status: Terminated

Product Description

Bupivacaine HCl 0.375% w/v and Lidocaine HCl 2% w/v Solution for Retrobulbar or Peribulbar Injection; packaged in a) 10 mL prefilled syringe, Item# 803, barcode 6919408031; b) 5 mL prefilled syringe, Item# 933, barcode 6919409331, Rx only, Pine Pharmaceuticals, 355 Riverwalk Parkway, Tonawanda, NY 14150.

Reason for Recall

Lack of Assurance of Sterility

Recalling Firm

Pine Pharmaceuticals, LLC — Tonawanda, NY

Classification

Class II — May cause temporary or medically reversible adverse health consequences.

Product Type

Drugs

Product Quantity

a) 920 syringes; b) 3263 syringes

Distribution

Product was distributed to direct accounts in AL, CA, NC and NY

Code Information

Lot #s: a) 58366, exp. date 09/26/2022; 60247, exp. date 12/04/2022; b) 54825, exp. date 08/10/2022; 57583, exp. date 08/22/2022; 59343, exp. date 10/30/2022; 60355, exp. date 10/11/2022

Status

Terminated

Voluntary / Mandated

Voluntary: Firm initiated